Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
Top Page
Livzon Pharmaceutical Group
(1513)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$29.00
▼(-6.27% Downside)
Action:ReiteratedDate:03/25/26
The score is driven mainly by solid financial performance (strong margins, mid-teens ROE, manageable leverage) and reasonable valuation with a high dividend yield. These positives are tempered by weak technicals, as the stock is in a broader downtrend and momentum remains negative despite oversold readings.
Positive Factors
Sustained Profitability
High gross and operating margins with mid-teens ROE indicate durable pricing power and operational efficiency. Over a 2–6 month horizon these fundamentals support sustained cash generation, margin resilience against cyclical swings, and capacity to fund R&D or product launches.
Negative Factors
Stagnant Revenue Trend
Flat to modestly declining revenues reduce growth optionality and raise reliance on margin improvements or cost cuts to drive earnings. Without clear product or market expansion, stagnant top-line limits durable earnings growth and constrains long-term reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Profitability
High gross and operating margins with mid-teens ROE indicate durable pricing power and operational efficiency. Over a 2–6 month horizon these fundamentals support sustained cash generation, margin resilience against cyclical swings, and capacity to fund R&D or product launches.
Read all positive factors
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.86B
Dividend Yield4.09%
Average Volume (3M)553.85K
Price to Earnings (P/E)11.6
Beta (1Y)0.71
Revenue Growth-0.45%
EPS Growth9.00%
CountryHK
Employees9,067
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.42
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio-8.67
Price to Book (P/B)1.65
Price to Sales (P/S)1.97
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.99Price Target Upside-25.69% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)2.29
Revenue Forecast (FY)HK$12.04B
Livzon Pharmaceutical Group Business Overview & Revenue Model
Company Description
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteri...
How the Company Makes Money
Livzon Pharmaceutical Group makes money primarily by selling pharmaceutical products. Key revenue streams generally include: (1) sales of finished pharmaceutical formulations (prescription drugs and other branded or generic medicines) to hospitals...
Livzon Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
81
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.60B | 11.81B | 12.43B | 12.63B | 12.06B |
| Gross Profit | 7.43B | 7.73B | 7.66B | 8.17B | 7.81B |
| EBITDA | 3.10B | 3.47B | 3.33B | 3.08B | 2.77B |
| Net Income | 1.97B | 2.06B | 1.95B | 1.91B | 1.78B |
Balance Sheet | |||||
| Total Assets | 24.00B | 24.46B | 25.04B | 24.86B | 22.37B |
| Cash, Cash Equivalents and Short-Term Investments | 10.93B | 10.92B | 11.41B | 10.52B | 9.33B |
| Total Debt | 3.85B | 3.93B | 3.48B | 3.62B | 2.69B |
| Total Liabilities | 8.20B | 9.55B | 10.28B | 9.93B | 8.06B |
| Stockholders Equity | 13.89B | 13.86B | 14.04B | 13.88B | 13.00B |
Cash Flow | |||||
| Free Cash Flow | 2.54B | 2.41B | 2.43B | 1.83B | 593.23M |
| Operating Cash Flow | 3.10B | 2.98B | 3.25B | 2.77B | 1.90B |
| Investing Cash Flow | -3.67B | -660.33M | -708.37M | -1.23B | -1.88B |
| Financing Cash Flow | -2.62B | -2.49B | -1.66B | -720.36M | -815.02M |
Livzon Pharmaceutical Group Technical Analysis
Negative
30.94
Price Trends
28.84
Negative
29.73
Negative
32.06
Negative
Market Momentum
-0.64
Positive
32.94
Neutral
27.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1513, the sentiment is Negative. The current price of 30.94 is above the 20-day moving average (MA) of 27.75, above the 50-day MA of 28.84, and below the 200-day MA of 32.06, indicating a bearish trend. The MACD of -0.64 indicates Positive momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of 27.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1513.
Livzon Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$24.07B | 22.15 | 12.37% | 3.13% | 10.56% | -13.58% | |
71 Outperform | HK$20.03B | 9.66 | 12.63% | 5.11% | 0.39% | 4.94% | |
70 Outperform | HK$30.86B | 11.61 | 14.53% | 4.09% | -0.45% | 9.00% | |
66 Neutral | HK$32.42B | 19.33 | 8.60% | 2.26% | 11.78% | 19.06% | |
61 Neutral | HK$35.43B | 6.37 | 7.91% | 2.95% | ― | ― | |
59 Neutral | HK$40.32B | 8.90 | 7.89% | 7.15% | 1.13% | -13.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1513
Livzon Pharmaceutical Group
27.18
0.83
3.16%
HK:3933
The United Laboratories International Holdings
10.15
-3.57
-26.04%
HK:0867
China Medical System Holdings
13.29
5.60
72.84%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.99
0.53
3.21%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.64
0.56
11.02%
HK:0512
Grand Pharmaceutical Group Limited
6.78
0.79
13.19%
Livzon Pharmaceutical Group Corporate Events
Livzon Pharmaceutical Strengthens Board Committees With New Appointments
Mar 24, 2026
Livzon Pharmaceutical Group has adjusted the composition of its board-level committees, reinforcing its corporate governance framework. The company appointed employee representative director Ms. Ran Yongmei to the Strategy Committee and executive ...
Livzon Pharmaceutical Outlines Board and Committee Structure
Mar 24, 2026
Livzon Pharmaceutical Group has disclosed the current composition of its board of directors and the membership of its five key board committees, reaffirming its corporate governance structure. The board comprises executive, non-executive, independ...
Livzon Pharmaceutical Proposes Final 2025 Dividend of RMB 14.3 per 10 Shares
Mar 24, 2026
Livzon Pharmaceutical Group Inc. has proposed a final ordinary cash dividend of RMB 14.3 per 10 shares for the financial year ended 31 December 2025, with the amount to be paid to Hong Kong shareholders to be translated into Hong Kong dollars at a...
Livzon Pharmaceutical Publishes Audited 2025 Results and Annual Report
Mar 24, 2026
Livzon Pharmaceutical Group announced its audited results for the year ended 31 December 2025, releasing the full 2025 Annual Report in compliance with Hong Kong listing requirements. The report, which includes management discussion, financial hig...
Livzon Pharmaceutical Cuts Registered Capital and Streamlines Board Structure
Mar 24, 2026
Livzon Pharmaceutical Group has updated its registered capital to RMB887,907,171 after changes in share capital arising from the exercise of share incentives and the cancellation of repurchased shares, resulting in 887,907,171 ordinary shares spli...
Livzon Wins Vietnam Approval for Tender Offer for Imexpharm Shares
Mar 6, 2026
Livzon Pharmaceutical Group has secured regulatory approval from the State Securities Commission of Vietnam for a voluntary public tender offer for shares in Imexpharm Corporation, a listed Vietnamese pharmaceutical company. The offer will be exec...
Livzon Pharmaceutical Sets March Board Meeting to Approve 2025 Annual Results
Mar 2, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 24 March 2026 to review and approve the audited annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider recommendi...
Livzon Pharmaceutical Announces Senior Leadership Reshuffle and Board Changes
Mar 1, 2026
Livzon Pharmaceutical Group announced that executive director and vice chairman Xu Guoxiang and non-executive director and vice chairman Tao Desheng have resigned upon reaching retirement age, relinquishing all roles in the group and its affiliate...
Livzon Pharmaceutical Group Details Board and Committee Structure
Mar 1, 2026
Livzon Pharmaceutical Group has detailed the current composition of its board of directors, naming executive, non-executive, employee representative and independent non-executive members, with Zhu Baoguo serving as chairman and Tang Yanggang as vi...
Livzon’s Psoriasis Biologic Lecankitug Enters China’s Priority Review Channel
Jan 7, 2026
Livzon Pharmaceutical Group’s subsidiary Livzon MABPharm has secured inclusion of its innovative biologic Lecankitug Injection in China’s priority review and approval process for marketing authorization, targeting adult patients with m...
Livzon Pharmaceutical Trims Stake in Fluffy Buddy Through Connected Deemed Disposal
Dec 30, 2025
Livzon Pharmaceutical Group has agreed to a connected transaction involving a capital increase and equity transfer at its subsidiary Fluffy Buddy, under which Xinyou Maohai will inject RMB15 million into Fluffy Buddy and acquire Joincare’s 4...
Livzon Extends Deadline and Launches Tender Offer Plan for Vietnam’s Imexpharm
Dec 30, 2025
Livzon Pharmaceutical Group has amended the terms of its planned acquisition of a controlling stake in Vietnam’s Imexpharm Corporation, extending the deadline for completion to 30 June 2026 and clarifying merger control conditions to ensure ...
Livzon Pharmaceutical Sets 2026 Caps on Connected Transactions With Livzon MAB
Dec 30, 2025
Livzon Pharmaceutical Group has approved and signed a series of 2026 framework agreements with its connected subsidiary Livzon MAB to govern continuing connected transactions for the year ending 31 December 2026. Under these agreements, the group ...
Livzon Sets 2026 Caps for Connected Transactions With Controlling Shareholder Joincare
Dec 30, 2025
Livzon Pharmaceutical Group has approved a new series of continuing connected transactions with its controlling shareholder Joincare for the 2026 financial year, covering the supply of utilities, mutual provision of labour services, and the sale a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.